ClinicalTrials.gg
RecruitingNCT06110130EMPA CKDUpdated Aug 21, 2026

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

A Phase 4 interventional study of Empagliflozin 10 MG and Placebo in Chronic Kidney Diseases, sponsored by Washington D.C. Veterans Affairs Medical Center. Recruiting at 1 site in United States. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Washington D.C. Veterans Affairs Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Planned enrollment
13th of 20
60 · median 77
Started
2024
with 4 others
Phase 4
9 of 20
5 open now
Registered
12th of 20
by date
Lead sponsor
2 of 20
Washington D.C. Veterans Affairs Medical Center

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 13th largest by planned enrollment, is one of 5 that started in 2024, is one of 9 in phase 4, and was the 12th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 19 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Primary Objective:

To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease (NDKD), on empagliflozin therapy.

Primary Endpoint: We will assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

Secondary Objectives:

  1. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR.
  2. Correlate systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12) , hs-CRP and arterial stiffness measures with urine exosome-based podocyte protein estimation [11, 27-29].
  3. Correlate urine podocyte-specific protein markers with APOL1 mRNA expression levels in blood mononuclear cells (MNC)
Read the detailed description

Chronic kidney disease (CKD) is a complex medical condition imposing deleterious effects on multiple organ systems. Prevention of increased cardiovascular mortality and progression to end-stage kidney disease (ESKD) are two major unmet medical needs in patients with CKD, with or without diabetes mellitus especially in those with albuminuria [1].

In patients with Non-Diabetic Kidney Disease (NDKD), the cornerstone of management includes blood pressure control, maintenance of normal body weight, dietary adherence, and avoidance of nephrotoxic drugs [2,3].

The management of diabetic kidney disease (DKD) has undergone extensive changes with the advent of several foundational classes of guideline based medical therapies (GDMT) for DKD. These include SGLT2i, GLP1-RAs, and Finerenone, along with Renin-Angiotensin System-inhibitors (RASi). While the benefits of the SGLT2i such as Empagliflozin for cardio-kidney outcomes in NDKD are well recognized from the landmark EMPA-KIDNEY trial [12], there is less understood in terms of mechanisms of benefit, especially in high-risk phenotypes for progression to kidney failure, such as APOL1 +ve gene mutation.

African Americans suffer from CKD at significantly higher rates and account for more than 35% of all patients receiving dialysis in the United States [1]. While T2D is the number one cause of CKD overall, and Black adults are twice as likely to develop T2D compared to White adults [1], recently identified genetic variants in the APOL1 gene may explain a significant proportion of the rising burden of albuminuric NDKD in African Americans (4). APOL1 risk variants G1 and G2 are trypanolytic factors that protect against trypanosomiasis but have been shown to be associated with significantly higher risk for development of NDKD (4). Though NDKD is quite prevalent in African-American patients, the precise mechanism of APOL1 risk variants involved in the pathogenesis and progression of NDKD in this patient population is unknown and requires further investigation [5,6], given the disproportionate burden of CKD and kidney failure in this population.

Abnormalities in podocyte biology play a central role in the pathogenesis of CKD. In CKD podocyte injury is a key component in the pathophysiology of the progressive kidney disease, which is also accompanied by systemic inflammation [6-8]. The degree of podocyte injury is currently best assessed by kidney biopsy, which is an invasive procedure and not performed in the vast majority of patients with CKD. Often times proteinuria accompanies the clinical picture. However non albuminuric CKD is a growing clinical entity. The patterns, and extent of podocyte injury in non-albuminuric CKD is less well understood([7,8] and their management is often challenging.

Several recent T2DM clinical trials have shown that SGLT2 inhibitors (SGLT2i) improve endothelial dysfunction. We and others [10,11] have shown decreased podocyte-specific urine protein injury markers production with SGLT2i in DKD [9-11]. Additionally, the literature suggests close cross-talk between the glomerular vascular endothelium and the podocyte [10]. The effect of SGLT2i on markers of podocyte injury, as well as markers of endothelial injury/inflammation deserve further elucidation. This maybe relevant in non albuminuric NDKD in lower eGFR stages (stages 3 and 4), albuminuric NDKD in stage 2, or more preserved eGFR states, in a population that may inherently be at high risk for progressive CKD and its subsequent rapid deterioration in kidney disease, such as APOL1 nephropathy.

In this pilot project, we plan to establish the degree to which podocyte inflammation or dysfunction in albuminuric or non-albuminuric NDKD, is modified by empagliflozin, an SGLT2i. Podocyte inflammation with increased excretion of podocyte-specific proteins such as Wilm's Tumor-1 has been noted in T2DM and other nephropathies [11,13-16]. We have studied and quantified the same biomarkers in diabetic nephropathy[11] and have also demonstrated amelioration and reduction of the same in DKD. However similar studies are lacking in NDKD, particularly in non albuminuric NDKD patients with low eGFR.

In this study, we focus on albuminuric or non-albuminuric NDKD where we would like to stratify two groups for inclusion: 1. Preserved eGFR such as 60 - 89 where we would like to see a concomitant UACR of at least 30 mg/g or 2. Less preserved eGFR between 20 - 59 with or without discernable albuminuria/UACR (see Inclusion criteria section of this protocol). This represents a wide range of baseline KDIGO risk using the KDIGO CKD heat map. The traditional method for assessing podocyte damage is by measuring urinary protein excretion. However other biomarkers may be more effective.

We and others have demonstrated that urinary exosomes are a defined entity in urine and estimation of podocyte specific proteins in urine exosomes may help identify and quantify podocyte inflammation [17-18].

Exosomes, are a class of extracellular vesicles, that are secreted from various tissues into the circulation or urine and they carry protein, nucleic acid and lipid cargoes and facilitate cell-to-cell communication. Exosomes have been proposed as potential biomarkers of specific physiological and pathological conditions. For example, exosomes have been implicated in the initiation and progression of diabetes mellitus and its complications [11,13]. However, the isolation of specific classes of exosomes in urine from CKD subjects to enable monitoring disease severity and level of inflammation has yet to be developed . Studying podocyte inflammation may also help to identify cross talk between podocyte , the glomerular endothelium, and systemic inflammation. [16-18] Moreover APOL1 mutation presence has been associated with progressive renal injury and even podocyte specific injury [19-24]. APOL1 mutation has been associated with systemic inflammation and podocytopathy, particularly in African Americans [24-26] Building on these preliminary data and literature review, the overall objective of this randomized, double-blinded, interventional, proof-of concept study is to understand the effect of empagliflozin 10 mg on markers of podocyte injury and systemic inflammation in patients with albuminuric or non-albuminuric NDKD. We plan to use singular 10mg dose (considered low dose) which has shown clinical efficacy in similar trials [12]. Please note our podocyte specific trial in diabetic CKD patients also used low dose SGLT2i, Canagliflozin 100mg [11] It will also explore the relationship between changes in markers of podocyte injury with the use of empagliflozin, in the backdrop of expression of APOL1 gene in individual patients. This will help elucidate mechanistic insights into the effects of SGLT2i on podocyte injury markers and markers of systemic inflammation in individuals with albuminuric or non-albuminuric NDKD, and further understand the effects in the backdrop of varying degrees of APOL1 expression.

03

Conditions studied

  • Chronic Kidney Diseases

Keywords

  • Non-diabetic
04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. African American veterans
  2. Age > 18 years
  3. ≥20-59 mL/min/1.73 m2 by the CKD-EPI equation, with or without any degree of albuminuria OR
  4. eGFR 60-89, with UACR of ≥30mg/g
  5. = 18-39.9
  6. Blood pressure controlled to ≤140/90
  7. Subjects without diabetes: will be screened using routine glucose level test: of less than 126 fasting glucose or less than 200mg/dl of random or post glucose blood glucose level in standard of care laboratory workup.
  8. Ability to provide before any trial related activities are conducted.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with Type 1 or Type 2 Diabetes Mellitus
  2. Any prescribed diabetes medication for patients, such as GLP1RA, SGLT2is, and sulphonylureas
  3. If a patient is on statin, need to be on a stable dose for a month.
  4. proven diagnosis of glomerular disease/glomerulonephritis
  5. Active smokers,
  6. Active skin wounds undergoing treatment or recent surgery within 1 month (due to possible aberrations in glycemic control)
  7. Women who are pregnant, planning to become pregnant, nursing mothers, women of not using measure
  8. to empagliflozin or any of the in Jardiance, reactions such as angioedema
  9. Patients on dialysis
  10. less than 20 mL/min/1.73 m2 by the CKD-EPI equation
  11. Planned surgery or planned hospital admission within 5 months of participation in the study
  12. At the discretion of PI to ensure health, safety, and well-being of the veteran, participation in this study may be stopped (please see withdrawal criteria)
  13. Patients with prior history of diagnosis of heart failure with documented EF of less than 50.
  14. Proven diagnosis of Polycystic Kidney Disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Placebo

    Placebo 10 mg orally daily

    Drug: Placebo

  • Active comparator
    Empagliflozin

    Empagliflozin 10 mg orally daily

    Drug: Empagliflozin 10 MG

Interventions

06

What researchers measure

Primary outcomes

  1. To study kidney dysfunction and podocyte specific injury

    To study kidney dysfunction and podocyte specific injury in African American Veterans with Non-diabetic kidney disease, following low dose of Empagliflozin therapy. Empagliflozin may be referred to as "Empa" hereafter. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR.

    Time frame: 3 years

Secondary outcomes

  1. Systemic inflammatory markers

    Correlate systemic inflammatory markers (focusing on vascular function and endothelium) that are already established such as interleukins and hs-CRP and arterial stiffness with urine exosome-based podocyte protein estimation To correlate urine podocyte-specific protein markers and serum inflammatory markers with APOL1 mRNA expression levels in blood mononuclear cells (MNC) (c-kit positive cells)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 45 months is close to that.

Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Feb 2, 2024
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06110130
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Responsible party
Sabyasachi Sen, MD, PhD (Chief of Endocrinology, Washington D.C. Veterans Affairs Medical Center) — Principal investigator
First posted
Oct 31, 2023
Start date
Feb 2, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Sabyasachi Sen, MD
Contact
sabyasachi.sen@va.gov
202-745-8000
Shannen Ubalde, BS
Contact
shannen.ubalde@va.gov
202-745-8000 ext. 55835
Sabyasachi Sen, MD
principal investigator · Washington VA Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion